As part of the rationalisation of its distributors network, Truscreen Limited (NZX: TRU) (“the Company”) is pleased to announce that it has appointed prominent medical…
Cervical cancer screening technology company TruScreen Limited (NZX:TRU) (the Company) has released its audited financial results for the year ended 31 March 2020.
Associate Professor Michael J. Campion, TruScreen Medical Advisory Committee member, sits down to discuss the science behind TruScreen's Cervical Cancer Screening Device, it's clinical validation…
Cervical cancer technology company, TruScreen Limited (NZAX:TRU), advises that it wishes to provide to shareholders a copy of its latest investor presentation.